Education
About Us
Working with TipRanks
Follow Us
Adagene (ADAG)
NASDAQ:ADAG
ADAG Stock Chart & Stats
$2.75
-$0.15(-7.28%)
At close: 4:00 PM EST
$2.75
-$0.15(-7.28%)
Day’s Range― - ―
52-Week Range$1.30 - $3.16
Previous CloseN/A
Volume1.51K
Average Volume (3M)94.20K
Market Cap
$129.61M
Enterprise Value$47.71M
Total Cash (Recent Filing)$62.83M
Total Debt (Recent Filing)$6.85M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Apr 01, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding47,131,270
10 Day Avg. Volume110,564
30 Day Avg. Volume94,199
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.42
Price to Sales (P/S)694.63
P/FCF Ratio-2.41
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue462.28
Enterprise Value/Gross Profit-42.47
Enterprise Value/Ebitda-1.34
Forecast
1Y Price Target
$8.50Price Target Upside209.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyEncouraging combination efficacy with pembrolizumab and a favorable safety profile, including low discontinuation and uncommon severe gastrointestinal toxicity, raises the probability of positive pivotal outcomes.
Partnerships And Development OptionalityMultiple upcoming data readouts and a collaboration with Roche expand validation opportunities and support potential label expansion and combination strategies beyond current indications.
Regulatory ProgressFDA Fast Track Designation for muzastotug along with regulatory alignment on later-stage trial design increases development clarity and could accelerate the path toward potential approval.
Bears Say
Binary Clinical Readout RiskUpcoming dose optimization and other pivotal readouts represent binary events that could trigger sharp downside if results are weaker than anticipated.
Investor Sentiment And LiquidityPersistent investor skepticism and low trading interest despite analyst positive views may keep valuation suppressed until consistent late-stage data materialize.
Share Price DisconnectShare price has not risen in line with clinically de-risking data and regulatory progress, indicating a market disconnect that could limit near-term upside.
Adagene News
ADAG FAQ
What was Adagene’s price range in the past 12 months?
Adagene lowest stock price was $1.30 and its highest was $3.16 in the past 12 months.
What is Adagene’s market cap?
Adagene’s market cap is $129.61M.
When is Adagene’s upcoming earnings report date?
Adagene’s upcoming earnings report date is Apr 01, 2026 which is in 58 days.
How were Adagene’s earnings last quarter?
Adagene released its earnings results on Aug 12, 2025. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.19 by -$0.04.
Is Adagene overvalued?
According to Wall Street analysts Adagene’s price is currently Undervalued.
Does Adagene pay dividends?
Adagene does not currently pay dividends.
What is Adagene’s EPS estimate?
Adagene’s EPS estimate is -0.28.
How many shares outstanding does Adagene have?
Adagene has 47,131,270 shares outstanding.
What happened to Adagene’s price movement after its last earnings report?
Adagene reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.19. Following the earnings report the stock price went down -13.613%.
Which hedge fund is a major shareholder of Adagene?
Currently, no hedge funds are holding shares in ADAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adagene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.97%
12-Months-Change
Fundamentals
Return on Equity
-63.41%
Trailing 12-Months
Asset Growth
-34.00%
Trailing 12-Months
Company Description
Adagene
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
ADAG Stock 12 Month Forecast
Average Price Target
$8.50
▲(209.09% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
11.78% Other Institutional Investors
88.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---